Figure 13.

Targeted delivery of self‐assembled poly (ethylene glycol)‐b‐poly(propylene sulfide) (PEG‐b‐PPS) micelles (MC) to Schlemm's canal endothelial cells for glaucoma treatment. a) Schematic illustration of peptide‐displaying micelles. b) The peptide‐targeting construct including PEG spacer, targeting peptide, and palmitoleic acid tail. c) LCMS spectra of the purified Flt4‐targeting peptide construct. d–f) Targeted delivery of latrunculin in mouse eyes. d) Illustrative overview of two different intraocular pressure (IOP) measurement schedules. Trials #1 and Trial #2 IOP timepoints presented with black and gray arrows, respectively. e) The Trial #1 consisted of 2 µL intracameral injection of black (BL)‐MC or tLatA MC (40 mg mL⁻¹, 5% peptide, 17 µM LatA). IOP was detected prior to injection, and after 24 and 48 h. f) In trial #2, 2 µL of BL‐MC, ntLatA‐MC, or tLatA‐MC (15.5 µM LatA, 40 mg mL⁻¹ 5% peptide) micelles were injected into one eye of 5 mice each. IOP was detected prior to injection and at three time points during a 48 h time course. Data presented as mean ± SEM (n = 5). Trial #1 and # 2 significance determined by unpaired t‐test and ANOVA with post hoc Tukey's multiple comparisons test (*p < 0.03), respectively. Reproduced with permission.^{[ 105 ]} Copyright 2020, Wiley‐VCH.